European equities traded in the US as American depositary receipts were treading water late Tuesday morning, edging 0.02% higher to 1,397.86 on the S&P Europe Select ADR Index.
From continental Europe, the gainers were led by medical device maker EDAP TMS (EDAP) and telecommunications company Nokia (NOK), which were up 2.4% and 1.6% respectively. They were followed by petroleum refiner Equinor (EQNR) and financial services company Banco Santander (SAN), which increased 1.4% and 1.1% respectively.
The decliners from continental Europe were led by biotech firm Evaxion Biotech (EVAX) and biopharmaceutical company DBV Technologies (DBVT), which shed 10% and 8.7% respectively. They were followed by biopharmaceutical company Genfit (GNFT) and pharmaceutical company Ascendis Pharma (ASND), which lost 3.3% and 2.4% respectively.
From the UK and Ireland, the gainers were led by biopharmaceutical companies NuCana (NCNA) and Adaptimmune Therapeutics (ADAP), which rose 8.2% and 6.9% respectively. They were followed by biotech firm Trinity Biotech (TRIB) and biopharmaceutical company Akari Therapeutics (AKTX), which advanced 5% and 3.2% respectively.
The decliners from the UK and Ireland were led by communications company WPP (WPP) and biopharmaceutical company Bicycle Therapeutics (BCYC), which dropped 5.7% and 4.2% respectively. They were followed by biotech firm Autolus Therapeutics (AUTL) and pharmaceutical company Silence Therapeutics (SLN), which were down 3.6% and 3.5% respectively.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.